FDA approves Cometriq (Exelixis Inc.) for treatment of Thyroid Cancer
The FDA on 29 November 2012 approved Cometriq (cabozantinib),formerly XL 184, from Exelixis Inc., to treat medullary Thyroid Cancer that has spread to other parts of the body (metastasized).
Cometriq is the second drug, with Caprelsa approved in April 2011 ,to treat medullary Thyroid Cancer in the past two years. The drug extended progression free survival for patients in a Phase III EXAM study to 11.2 months compared with four months with a placebo.
EMA has on the same day accepted the MAA for Cometriq from Exelixis Inc., for the proposed indication of progressive unresectable, locally advanced, Thyroid Cancer.
150 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.